NCT05084222View on ClinicalTrials.gov

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Asthma
Interventions
DRUG

Buventol® Easyhaler® 200 µg/inhalation dmDPI

Two doses will be administered

DRUG

Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI

Two doses will be administered

DRUG

Ventoline® Evohaler® 100 µg/inhalation pMDI

Four doses will be administered via Volumatic spacer

Trial Locations (2)

33520

Tampere University Hospital, Tampere

00029

Helsinki University Hospital, Helsinki

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT05084222 - Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing | Biotech Hunter | Biotech Hunter